BioMedNewsBreaks

ThursdayJul 14, 2022 1:59 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are…

Continue Reading

ThursdayJul 14, 2022 11:20 am

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., will be featured in a new interview aired by RedChip Companies on The RedChip Money Report(R) on Bloomberg TV at 7 p.m. Eastern Time this Saturday, July 16. Bloomberg TV is available in an estimated 73 million homes across the U.S. In the exclusive interview, Odyssey Health’s spokesperson and Pro Football Hall of Fame quarterback Brett Favre discusses the major concussion he sustained in the final play of his professional career. Favre will share why he is proudly working to reduce and prevent concussions, the potential of Odyssey’s concussion treatment, and…

Continue Reading

WednesdayJul 13, 2022 4:09 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs. “This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14…

Continue Reading

WednesdayJul 13, 2022 2:57 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach discusses her soccer career and why she was drawn to Odyssey, a medical technology company that is developing a drug/device combination intended to treat concussion. Wambach and other members of the sports advisory board support the company’s efforts to enhance public awareness of traumatic brain…

Continue Reading

WednesdayJul 13, 2022 2:31 pm

BioMedNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma. The company is diligently pursuing the clinical development of FSD201 for various indications. FSD Pharma recently announced the submission of an Investigational New Drug…

Continue Reading

TuesdayJul 12, 2022 4:45 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point…

Continue Reading

TuesdayJul 12, 2022 3:23 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

Continue Reading

TuesdayJul 12, 2022 3:08 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions worldwide, while a single concussion can significantly increase the risk of Alzheimer’s and other neuropsychiatric disorders. “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will…

Continue Reading

MondayJul 11, 2022 11:44 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1…

Continue Reading

FridayJul 08, 2022 2:54 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients

Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine Ann Denny, an associate professor of clinical neurobiology, saying: “To bring hope and possibly a therapeutic to patients suffering from Alzheimer’s Disease is an exciting proposition for Silo Pharma.” Alongside its work with Columbia University, Silo has partnered with Zylo Therapeutics to use Zylo’s Z-pod…

Continue Reading